Sage Journals: Discover world-class research

Abstract

Located at the interface of the circulation system and the CNS, the basement membrane (BM) is well positioned to regulate blood–brain barrier (BBB) integrity. Given the important roles of BBB in the development and progression of various neurological disorders, the BM has been hypothesized to contribute to the pathogenesis of these diseases. After stroke, a cerebrovascular disease caused by rupture (hemorrhagic) or occlusion (ischemic) of cerebral blood vessels, the BM undergoes constant remodeling to modulate disease progression. Although an association between BM dissolution and stroke is observed, how each individual BM component changes after stroke and how these components contribute to stroke pathogenesis are mostly unclear. In this review, I first briefly introduce the composition of the BM in the brain. Next, the functions of the BM and its major components in BBB maintenance under homeostatic conditions are summarized. Furthermore, the roles of the BM and its major components in the pathogenesis of hemorrhagic and ischemic stroke are discussed. Last, unsolved questions and potential future directions are described. This review aims to provide a comprehensive reference for future studies, stimulate the formation of new ideas, and promote the generation of new genetic tools in the field of BM/stroke research.

Keywords

Stroke intracerebral hemorrhage brain ischemia blood–brain barrier basement membrane

Introduction

The basement membrane (BM) is an amorphous structure located at the abluminal side of endothelial cells or basal side of epithelial cells.^1–5 It is composed of multiple highly organized extracellular matrix (ECM) proteins and has a thickness of 50–100 nm.^6–11 The four major types of ECM proteins found in the BM are collagen IV, laminin, nidogen, and heparan sulfate proteoglycans (HSPGs).^1,2,12,13 In addition, some other components, including fibulins, osteonectin and netrin-4, are also found in the BM.^3,14–20

In the brain, the BM is predominantly associated with blood vessels. Unlike peripheral organs, the brain has two different BMs: an endothelial BM made mainly by BMECs and a parenchymal BM produced primarily by astrocytes (Figure 1(a) and (b)).^21–23 Sandwiched between endothelial cells and astrocytic endfeet, pericytes also contribute to BM formation by synthesizing and depositing ECM proteins to endothelial and/or parenchymal BMs. These two BMs are separated by pericytes and appear as one in regions without pericytes in physiological conditions (Figure 1(a) and (b)).^21,22 During neuroinflammation, however, these two BMs can be separated at postcapillary venules by infiltrating leukocytes,^1,24 forming perivascular cuffs. Located at the interface of the circulation system and the CNS, the BM is well positioned to regulate blood–brain barrier (BBB) integrity under both homeostatic and pathological conditions.

Figure 1.

Anatomical location of the BMs at the BBB. (a) Diagram illustration of the endothelial and parenchymal BMs at the BBB. (b) An electron microscopy image showing endothelial and parenchymal BMs at the BBB. BM: basement membrane; BBB: blood–brain barrier. (c) The cellular source of different laminin isoforms and their distribution in the endothelial and parenchymal BMs. (d) Changes of the four major BM components after hemorrhagic and ischemic stroke.

Here in this review, I first briefly introduce the composition of brain BMs. Next, the functions of the BM and its major components in BBB maintenance and stroke pathogenesis are discussed and summarized. Furthermore, unsolved questions, current challenges, and potential future directions are described. This review aims to provide a comprehensive reference for future studies, stimulate the formation of new ideas, and promote the generation of new genetic tools in the field of BM/stroke research.

BM composition

Brain BMs mainly consist of collagen IV, laminin, nidogen, and HSPGs.^1,2,12,13 The structure of each component and their expression in cerebral blood vessels are discussed below.

Collagen IV

Collagen IV is the most abundant component of the BMs. It is a trimeric protein containing three α chains. Currently, 6 collagen IV α chains (Col4a1-6) have been identified.^25–30 Each α chain contains an N-terminal 7S domain, a triple-helical domain, and a C-terminal globular non-collagenous-1 (NC1) domain (Figure 2(a)). During collagen IV network assembly, three α chains bind to each other forming a trimer, called protomer. These protomers then dimerize via their NC1 domains and tetramerize through their 7S domains, forming sheet-like suprastructures (Figure 2(a)).^2,31,32 In the cerebrovasculature, collagen IV is predominantly produced by endothelial cells,^33–35 astrocytes,^33,36 and pericytes.³⁷

Figure 2.

Structures of major BM components. (a) Structures of collagen IV monomer (α chain), trimer (protomer), and network. (b) Structure of a fully assembled laminin molecule. (c) Structure of nidogen-1/2. (d) Structure of HSPG2. BM: basement membrane; HSPG2: heparan sulfate proteoglycan-2.

Laminin

Laminin is a large family of cross-shaped heterotrimeric proteins composed of α, β, and γ subunits.^22,38–41 Each laminin subunit contains various globular (LN, L4, and LF) domains, rod-like (LE) repeats, and a coiled-coil domain (Figure 2(b)).^41,42 Unique to all α subunits are five globular (LG) domains at the C-terminus (Figure 2(b)).^41,42 These subunits bind to each other through their C-terminal coiled-coil domains, forming a large laminin molecule with one long arm and two or three short arms (Figure 2(b)).⁴¹ So far, there are five α, four β, and three γ variants.⁴¹ Various combinations of these subunits generate a large number of different laminin isoforms.^43,44 It is worth noting that not all possible combinations have been experimentally confirmed. In mammals, 20 laminin isoforms have been identified or proposed based on in vivo and in vitro studies (Table 1).⁴⁴ Like collagen IV, laminins are able to form sheet-like suprastructures via intermolecular self-assembly at their N-terminal domains.⁴⁵

Table 1.

Laminin isoforms.

Original name	Alternative name	Abbreviation
Laminin-1	Laminin-α1β1γ1	Laminin-111
Laminin-2	Laminin-α2β1γ1	Laminin-211
Laminin-3	Laminin-α1β2γ1	Laminin-121
Laminin-4	Laminin-α2β2γ1	Laminin-221
Laminin-5(A)	Laminin-α3(A)β3γ2	Laminin-3(A)32
Laminin-5B	Laminin-α3Bβ3γ2	Laminin-3B32
Laminin-6	Laminin-α3β1γ1	Laminin-311
Laminin-7	Laminin-α3β2γ1	Laminin-321
Laminin-8	Laminin-α4β1γ1	Laminin-411
Laminin-9	Laminin-α4β2γ1	Laminin-421
Laminin-10	Laminin-α5β1γ1	Laminin-511
Laminin-11	Laminin-α5β2γ1	Laminin-521
Laminin-12	Laminin-α2β1γ3	Laminin-213
Laminin-13	Laminin-α3β2γ3	Laminin-323
Laminin-14	Laminin-α4β2γ3	Laminin-423
Laminin-15	Laminin-α5β2γ3	Laminin-523
–	Laminin-α2β1γ2	Laminin-212
–	Laminin-α2β2γ2	Laminin-222
–	Laminin-α3β3γ3	Laminin-333
–	Laminin-α5β2γ2	Laminin-522

Two nomenclature systems exist for laminins. The original system names laminins using numbers based on the order of their discovery, such as laminin-1, laminin-2, and so on.⁴⁶ The alternative system names laminins using both Greek letters and numbers, which indicate the subunits and genetic variants, respectively.⁴³ For example, laminin-1 is written as laminin-α1β1γ1, which can be abbreviated as laminin-111. Compared to the original system, the alternative system provides information regarding the trimeric composition of laminins, and thus is more widely used nowadays. A comparison of these two nomenclature systems is illustrated in Table 1.

In the cerebrovasculature, laminins are made by endothelial cells, astrocytes, and pericytes.^22,47,48 Interestingly, these cells synthesize different laminin isoforms. Specifically, endothelial cells mainly make laminin-411 and -511,^21,49,50 whereas astrocytes predominantly produce laminin-211.^21,51 Our unpublished data show that pericytes mainly synthesize γ1- and α4/α5-containing laminins (most likely laminin-421 and -521). This cell-specific expression pattern allows differential distribution of distinct laminin isoforms in the endothelial and parenchymal BMs: the former is rich in laminin-411 and -511, while the latter mainly contains laminin-211 (Figure 1(c)).²²

Nidogen

Nidogen, also known as entactin, is a glycoprotein containing three globular (G1-3) and multiple rod-like (Link, EFG, and Thyroglobulin) domains (Figure 2(c)). In mammals, two genetic variants of nidogen (nidogen-1/2) have been identified. Unlike collagen IV and laminin, nidogens are unable to self-assemble or form sheet-like supramolecules. They can, however, interact with collagen IV and laminin via different domains, suggesting that they may function as a cross-linker to connect/stabilize collagen IV and laminin networks. Nidogens are mainly generated by endothelial cells,³⁵ astrocytes,⁵² and pericytes^35,53 in the cerebrovascular system.

HSPG

One important HSPG is heparan sulfate proteoglycan-2 (HSPG2), also called perlecan. It is a large multi-function protein composed of five domains (domain I-V) (Figure 2(d)).^54–57 Domain I has three glycosaminoglycans and a sea urchin sperm protein-enterokinase-argin (SEA) motif; Domain II contains four low-density lipoprotein (LDL) receptor class A repeats and an immunoglobulin (Ig) domain; Domain III has multiple laminin B and laminin EGF domains; Domain IV consists of a series of Ig domains; and Domain V, also known as endorepellin, contains many laminin G and EGF domains. Like nidogen, HSPG2 cannot form supramolecular sheet-like structures.⁵⁴ Instead, it is able to interact with many molecules,^54,57–65 including other BM components (ECM proteins) and heparin-binding growth factors. Similarly, HSPG2 expression is detected in endothelial cells,^66–68 astrocytes,^69,70 and pericytes³⁵ in cerebral blood vessels.

BM and BBB

In physiological conditions, the BMs play a variety of important roles, ranging from providing structural support to modulating molecular signaling.^22,71 In addition, accumulating evidence suggests that the BMs also contribute to vascular integrity. For example, leukocytes are more frequently observed between endothelial cells and the underlying BMs than in the process of passing between endothelial cells, in electron microscopy studies.^72–74 In addition, it has been reported that: (1) leukocytes take ∼5 min to cross the endothelial layer, but 20–30 min to penetrate the underlying BMs^75–78; and (2) T lymphocytes spend 9-10 min crossing the endothelium, but are trapped in the outer surface of blood vessels for ∼30 min.⁷⁹ These results strongly indicate that crossing the BMs is the rate-limiting step in leukocyte infiltration, highlighting a critical role of the BMs in the maintenance of vascular integrity.

In the brain, the BMs are located at the interface of the circulation system and the CNS (Figure 1).^80,81 This unique anatomical structure/location, together with that the BM is a non-cellular component of the BBB, suggests that the BMs also participate in the regulation of BBB integrity. The BMs may exert this important function directly by serving as a physical barrier at the BBB or indirectly by signaling to endothelial cells, astrocytes, and/or pericytes. In support of the latter possibility, receptors for BM components (ECM proteins), including integrins and dystroglycan, have been identified in these cells.^40,47 More importantly, genetic ablation of these receptors and their respective ligands usually results in similar phenotypes,^12,40,41,48 strongly suggesting that ECM proteins exert functions by binding to their receptors. Below, we discuss the function of each major BM component in BBB maintenance.

Collagen IV

Col4a1/2, two of the most frequently used α chains, make the major collagen IV isoform α1(IV)₂α2(IV). Genetic ablation of Col4a1/2 leads to embryonic lethality at embryonic day (E) 10.5-11.5.⁸² Interestingly, BM defects were detected in these mutants at E10.5–11.5 but not before E9.5,⁸² suggesting that collagen IV is dispensable for initial BM assembly but essential for BM maintenance and function. To overcome the embryonic lethality, a series of less severe mutations in Col4a1/2 have been generated in mice.^83,84 These mutants develop CNS phenotypes, including compromised vascular integrity, stress-induced hemorrhage and adult-onset stroke, to various degrees (see “Collagen IV changes in hemorrhagic stroke” section for details),^83–85 suggesting an indispensable role of collagen IV in the maintenance of cerebrovascular integrity.

Laminin

Since different cells synthesize distinct laminin isoforms, laminin’s functions are discussed in a cell-specific manner. Endothelial cells mainly make laminin-411 and -511.^21,49,50 It has been shown that ablation of laminin α4 leads to disrupted vascular integrity and hemorrhage at embryonic and perinatal stages, but not in adulthood.⁸⁶ This age-dependent phenotype is due to compensatory and ubiquitous expression of laminin α5 in the vascular tree at postnatal stage.⁸⁷ Unlike laminin α4, laminin α5,⁸⁸ β1,^89,90 or γ1,^91–92 null mice are embryonic lethal, preventing investigation of their functions in BBB integrity. To overcome this early lethality and enable such investigation, laminin α5 endothelium-specific (Tie2-Cre) conditional knockout (α5-TKO) mice were generated. Using two different laminin α5-floxed lines, our group (unpublished data) and others^93,94 independently demonstrate that α5-TKO mice develop normally without BBB defects under homeostatic conditions, suggesting a dispensable role of endothelial laminin α5 in BBB maintenance. Due to potential compensation between laminin-411 and -511, it remains unclear how endothelial laminin regulates BBB integrity under physiological conditions. We are currently generating transgenic mice lacking both laminin isoforms in endothelial cells. These mutants will enable us to answer this important question.

Unlike endothelial cells, astrocytes predominantly produce laminin-211.^21,51 To investigate the role of astrocytic laminin in BBB integrity, we generated neural progenitor- and neuron-specific laminin γ1 conditional knockouts by crossing the laminin γ1^flox/flox mice⁹⁵ with nestin-Cre and CaMK2a-Cre transgenic lines, respectively. The former mutants (termed NKO hereafter) have laminin deficiency in both neurons and glial cells, while the latter mutants (termed CKO hereafter) have laminin deficiency in neurons only. NKO but not CKO mice display BBB disruption⁹⁶ and age-dependent hemorrhagic stroke,⁹⁷ suggesting that astrocytic rather than neuronal laminin is required for BBB maintenance. Consistent with this finding, laminin α2 null mice develop severe BBB breakdown,⁹⁸ again suggesting an indispensable role of astrocytic laminin in BBB maintenance.

In addition to endothelial cells and astrocytes, pericytes also synthesize and deposit laminins into the BMs. Although laminin α2 mRNA was found in pericytes in next-generation sequencing,⁹⁹ our unpublished data show that pericytes mainly produce γ1 - and α4/α5-containing laminins. To investigate the function of pericytic laminin, pericytic laminin conditional knockouts (PKO) were generated by crossing the laminin γ1^flox/flox mice with the Pdgfrβ-Cre line. It should be noted that there is no pericyte-specific marker available currently,¹⁰⁰ and that PDGFRβ marks both pericytes and vascular smooth muscle cells (vSMCs).^100,101 Thus, laminin is abrogated in both pericytes and vSMCs in PKO mice. To distinguish pericyte- and vSMC-derived laminins, vSMC-specific conditional knockouts (SKO) were generated by crossing the laminin γ1^flox/flox mice with the SM22α-Cre line. In the C57Bl6-FVB mixed background, the PKO mice usually die within four months and show hydrocephalus & BBB breakdown/micro-hemorrhages with incomplete penetrance.¹⁰¹ These changes, however, are absent in SKO mice,^101,102 suggesting a critical role of pericyte- rather than vSMC-derived laminins in BBB maintenance. Since hydrocephalus itself can compromise BBB integrity, it is not clear if the BBB breakdown phenotype is caused by loss of pericytic laminin or secondary to hydrocephalus. Based on that hydrocephalus is highly genetic background dependent,^103–106 we crossed the PKO mice into various genetic backgrounds, aiming to reduce the incidence of hydrocephalus. Our unpublished data show that, in the C57Bl6 background, the PKO mice develop mild and age-dependent BBB disruption without hydrocephalus or micro-hemorrhages, strongly indicating that pericytic laminin also contributes to BBB maintenance under homeostatic conditions, although to a lesser extent compared to astrocytic laminin. The cellular source of different laminin isoforms and their distribution in endothelial and parenchymal BMs are summarized in Figure 1(c). The major phenotypes of these laminin mutant mice are summarized in Table 2.

Table 2.

Laminin mutants and their phenotypes.

Laminin mutations	Type of mutation	Cre lines	Target cells	CNS phenotypes	References
Laminin α2^−/−	Global knockout	–	All cells	BBB breakdown	⁹⁸
Laminin α4^−/−	Global knockout	–	All cells	Hemorrhage at embryonic and perinatal stages	⁸⁶
Laminin α5^−/−	Global knockout	–	All cells	Embryonic lethality around E17 and exencephaly	⁸⁸
Laminin β1^−/−	Global knockout	–	All cells	Embryonic lethality at E5.5 and lack of BMs	^89,90
Laminin γ1^−/−	Global knockout	–	All cells	Embryonic lethality at E5.5 and lack of BMs	^89–92
Laminin α5 -ΤKO	Conditional knockout	Tie2-Cre	Endothelial cells	Grossly normal under homeostatic conditions	^93,94 Unpublished data
Laminin γ1-NKO	Conditional knockout	Nestin-Cre	Neural progenitor cells	Severe BBB disruption and age-dependent spontaneous hemorrhagic stroke	^96,97
Laminin γ1-CKO	Conditional knockout	CaMK2a-Cre	Forebrain neurons	Grossly normal under homeostatic conditions	^96,97
Laminin γ1-PKO	Conditional knockout	Pdgfrβ-Cre	Pericytes and vSMCs	In the C57Bl6-FVB mixed background: hydrocephalus, BBB compromise and micro-hemorrhages (incomplete penetrance)	¹⁰¹
Laminin γ1-PKO	Conditional knockout	Pdgfrβ-Cre	Pericytes and vSMCs	In the C57Bl6 background: age-related mild BBB compromise	Unpublished data
Laminin γ1-SKO	Conditional knockout	SM22α-Cre	vSMCs	Grossly normal under homeostatic conditions	^101,102

CNS: central nervous system; vSMCs: vascular smooth muscle cells.

Nidogen

Genetic abrogation of either nidogen-1^107–110 or nidogen-2¹¹¹ results in a grossly normal phenotype, suggesting that they may be able to compensate for each other’s loss in these single mutants. Consistent with this hypothesis, nidogen-1/2 double knockout mice die shortly after birth and show severe BM defects in multiple organs,^112,113 suggesting an important role of nidogen-1/2 in BM maintenance. Based on the observed BM defects in the brain, we expect that BBB integrity is compromised in these double mutants. This hypothesis needs further validation/investigation in future studies.

HSPG

Global knockout of HSPG2 leads to severe developmental defects in multiple organs.^114,115 The mutants die either around E11 or at the perinatal stage due to defective cephalic, myocardial, and skeletal development.^114,115 Although BM formation is not affected, BMs deteriorate in areas with increased mechanical stress in these mutants,¹¹⁴ indicating an essential role of HSPG2 in BM maintenance rather than assembly. Consistent with BM changes, a hemorrhagic phenotype in the brain, skin and lung is observed in these mutants,¹¹⁴ suggesting that HSPG2 is required for the maintenance of vascular integrity.

BM and stroke

Stroke is a clinical emergency caused by rupture (hemorrhagic) or occlusion (ischemia) of cerebral blood vessels. It is the fifth leading cause of death and the leading cause of serious long-term disability in the United States.¹¹⁶ One key pathological change after stroke is inflammatory cell infiltration across the compromised BBB, which profoundly influences disease progression. Due to their important roles in BBB maintenance and vascular integrity, the BMs have been hypothesized to affect inflammatory cell extravasation and stroke pathogenesis. Previous studies have demonstrated that immune cell infiltration predominantly occurs at specific low expression regions characterized by reduced expression of certain BM constituents.^87,117–121 For example, neutrophils^117–120 and monocytes¹¹⁷ preferentially penetrate the BM in regions with reduced levels of laminin α5 and collagen IV in peripheral tissues. In addition, in both lymph nodes and brains, T lymphocytes mainly extravasate across blood vessels through laminin α4^high and laminin α5^low regions.^87,121 It is speculated that inflammatory cells use these low expression regions to infiltrate the brain after stroke. However, due to the lack of knowledge on the alterations of specific laminin isoforms after stroke and the existence of controversial results on how collagen IV/laminin change after ischemic stroke (Figure 1(d)), the function of the BM in inflammatory cell extravasation after stroke remains largely unknown and needs further investigation. Here, we discuss BM changes and functions in both hemorrhagic and ischemic stroke.

BM and hemorrhagic stroke

Multiple studies have shown that the BM negatively correlates with hemorrhagic stroke. For example, BM degradation has been reported in rats at 24–72 h after subarachnoid hemorrhage¹²² and in mice with age-dependent spontaneous intracerebral hemorrhage (ICH).⁹⁷ In addition, loss of BM components and/or their mutations usually lead to BM defects and hemorrhagic stroke (see below for details). BM loss during hemorrhagic stroke may be caused by diminished ECM protein synthesis or increased ECM protein degradation. We lean towards the second possibility. This is because: (1) ECM proteins usually have a long turnover rate,¹²³ and (2) various ECM-degrading proteases, including matrix metalloproteinases (MMPs) and thrombin, are dramatically induced/activated after hemorrhagic stroke.^124–132 Changes of major BM components after hemorrhagic stroke are discussed below and summarized in Figure 1(d).

Based on these findings, it is logical to hypothesize that inhibiting BM-degrading enzymes and/or supplementing BM components may have a therapeutic potential in hemorrhagic stroke. Consistent with this speculation, various MMP inhibitors, including minocycline, GM6001 and BB-1101, have been found beneficial in hemorrhagic stroke.^124,133,134 In contrast to these results, BB-94, another broad-spectrum MMP inhibitor, has been reported to increase hematoma size and apoptosis after hemorrhagic stroke.¹³⁵ In addition, minocycline failed to affect clinical and radiological outcomes in patients with hemorrhagic stroke in a pilot study.¹³⁶ This inconsistency may be due to different experimental models and/or low specificity of these MMP inhibitors. We are currently investigating the therapeutic potential of exogenous BM components in hemorrhagic stroke.

Collagen IV changes in hemorrhagic stroke

Accumulating evidence suggests that collagen IV plays a pivotal role in the pathogenesis of hemorrhagic stroke. First, collagen IV is negatively associated with hemorrhage in the brain. Reduced collagen IV expression is found in mice lacking endothelial expression of serum response factor, which develop ICH.¹³⁷ Similarly, dramatically lower levels of collagen IV are detected in the hemorrhagic regions in ischemic brain.¹³⁸ Second, loss of collagen IV plays a causative role in hemorrhagic stroke. For example, collagenase, which degrades collagen IV, is widely used to induce ICH in rodents.^139–141 Third, loss-of-function mutations in Col4a1/2 cause ICH to various degrees. It has been shown that mice with a splice-site mutation that skips Col4a1 exon 41 (Col4a1^Δex^/+) display perinatal cerebral hemorrhage associated with birth trauma.^85,142 Although surgically delivered mutants do not show cerebral hemorrhage at the perinatal stage, they develop ICH in adulthood.^85,143 Cellular studies demonstrate that this mutation leads to synthesis of mutant collagen IV protein, which cannot be secreted and thus is accumulated inside cells.^83,142,144 To further investigate the molecular mechanism underlying the hemorrhagic phenotype, Col4a1 mutants containing loxP flanked exon 41 (Col4a1^Flex41/+) were generated.⁸⁵ By crossing this line with an inducible ubiquitous Cre line (R26-Cre^ER) and/or various cell-specific Cre lines (Tie2-Cre, Pdgfrβ-Cre, Gfap-Cre), this mutation was induced at different developmental stages and/or in different cell types. It has been shown that induction of such mutation: (1) at embryonic and early postnatal stages, but not in adulthood, causes age-related ICH⁸⁶; and (2) in endothelial cells and/or pericytes but not astrocytes leads to ICH.⁸⁵ These findings suggest that endothelium- and/or pericyte-derived Col4a1 plays an important role in cerebrovascular development rather than maintenance. Additionally, although not as severe as Col4a1^Δex41/+ mutants, mice with various point-mutations (G394V, G658D, G912V, G1038S, G1180D, G1344D, and S1582P) in Col4a1 develop ICH to various degrees.^84,85 Similarly, a point mutation (G646D) in Col4a2 also results in mild ICH.^84,85,144 The severity of ICH in these Col4a1/2 mutants is summarized in Table 3. Consistent with these animal studies, mutations in Col4a1/2 have also been identified in human patients with hemorrhagic stroke.^84,143–158 Together, these results suggest a crucial role of collagen IV in the pathogenesis of hemorrhagic stroke.

Table 3.

Collagen IV mutants and their phenotypes.

Collagen IV mutations	Type of mutation	Cre lines	Target cells	CNS phenotypes	Severity of ICH	References
Col4a1/2^−/−	Global knockout	–	All cells	Embryonic lethality at E11, BM defects	–	⁸²
Col4a1^Δex41/+	Skipping exon 41	–	All cells	ICH, porencephaly	Severe	^85,142,143
Col4a1^Flex41/+	Inducible conditional knockout	R26-Cre^ER	All cells with tamoxifen	ICH and macroangiopathy	Depending on induction time	⁸⁵
	Conditional knockout	Tie2-Cre	Endothelial cells	ICH, porencephaly and macroangiopathy	Moderate	⁸⁵
	Conditional knockout	Pdgfrβ-Cre	Pericytes and vSMCs	ICH, porencephaly and macroangiopathy	Moderate	⁸⁵
	Conditional knockout	Gfap-Cre	Astrocytes	ICH	Very mild	⁸⁵
Col4a1^G394V/+	Point mutation	–	All cells	ICH	Mild	^84,85
Col4a1^G658D/+	Point mutation	–	All cells	ICH	Mild	^84,85
Col4a1^G912V/+	Point mutation	–	All cells	ICH	Mild-moderate	^84,85
Col4a1^G1038S/+	Point mutation	–	All cells	ICH	Moderate	^84,85
Col4a1^G1180D/+	Point mutation	–	All cells	ICH	Moderate	^84,85
Col4a1^G1344D/+	Point mutation	–	All cells	ICH	Moderate	^84,85
Col4a1^S1582P/+	Point mutation	–	All cells	No ICH	-	^84,85
Col4a2^G646D/+	Point mutation	–	All cells	ICH	Mild	^84,85,144

ICH: intracerebral hemorrhage; CNS: central nervous system.

Laminin changes in hemorrhagic stroke

Due to the substantial up-regulation and activation of various BM-degrading proteases after hemorrhagic stroke, laminin levels are expected to decrease in hemorrhagic brains. Consistent with this hypothesis, significantly lower levels of laminin were found in hemorrhagic areas compared to non-hemorrhagic areas in ischemic brain.¹⁵⁹ Interestingly, loss of laminin is associated with hemorrhagic stroke in an isoform-specific manner. First, a previous study from our laboratory showed that NKO but not CKO mice developed age-dependent spontaneous ICH,⁹⁷ suggesting a causative role of loss of astrocytic laminin (laminin-211) in hemorrhagic stroke. Next, although micro-hemorrhages and hydrocephalus occur hand-in-hand in PKO mice in the C57Bl6-FVB mixed background, micro-hemorrhages are absent in these mutants in the C57Bl6 background when the incidence of hydrocephalus is reduced to a negligible level. These findings suggest that micro-hemorrhages in PKO mice in the mixed background are probably secondary to hydrocephalus and that loss of pericytic laminin does not cause hemorrhagic stroke. Additionally, due to potential compensation between laminin-411 and -511, whether loss of endothelial laminin results in hemorrhagic stroke remains unknown. Mice with endothelium-specific ablation of both laminin-411 and -511 will enable us to answer this important question.

Nidogen changes in hemorrhagic stroke

How nidogen levels change in hemorrhagic stroke remains largely unknown. One in vitro study showed that nidogen fragmentations were found in astrocyte medium after exposure to plasma kallikrein,¹⁶⁰ suggesting that nidogen may be degraded after hemorrhagic stroke. This result needs to be validated in vivo using hemorrhagic models. Due to the grossly normal phenotype of nidogen-1/2 single knockouts and the perinatal lethality of the double knockouts, the role of nidogen in the pathogenesis of hemorrhagic stroke remains unclear. Mice with simultaneous deletion of nidogen-1/2 in different cell types (conditional nidogen-1/2 double knockouts) will provide insights into the function of nidogen in hemorrhagic stroke.

HSPG changes in hemorrhagic stroke

Like nidogen, how hemorrhagic stroke affects HSPG2 level is unclear. In addition, due to early embryonic lethality, the function of HSPG2 in the development and progression of hemorrhagic stroke is unknown. Similarly, HSPG2 conditional and/or inducible knockout mice will enable us to answer these important questions.

BM and ischemic stroke

Similar to hemorrhagic stroke, BM dissolution is associated with ischemic stroke. For example, loss of BM is found soon after the onset of ischemia.¹⁶¹ In addition, it has been reported that BM degradation occurs as early as 10 min after reperfusion in the middle cerebral artery occlusion (MCAO) model,¹⁶² and that loss of BM can be detected as early as 1–3 h after ischemia.^161,162 Ultrastructurally, the well-defined electron-dense BMs become diffused and faint after ischemia.^163,164 Biochemically, many BM components are degraded and reduced after ischemic stroke.^161,165 Like in hemorrhagic stroke, BM loss in ischemic stroke is mainly due to enhanced protein degradation rather than reduced protein synthesis. This is supported by the following observations. First, MMP expression and their activities are markedly up-regulated after ischemic stroke.^166–171 Second, the expression levels and enzymatic activities of cathepsin B and L, which primarily degrade HSPG2 and other cellular components,¹⁷² are dramatically enhanced after ischemia.^172,173 The changes of major BM components after ischemic stroke are discussed below and summarized in Figure 1(d).

Recombinant tissue-type plasminogen activator (tPA) is the only FDA-approved therapy for ischemic stroke. tPA exerts its protective effects by inducing plasmin-dependent fibrinolysis inside blood vessels.¹⁷⁴ However, with the progression of disease, tPA leaks out of blood vessels through compromised BBB. Outside blood vessels, tPA substantially enhances MMP-9 levels and exaggerates MMP-mediated BM degradation.^175–177 This deleterious effect outside blood vessels may explain the short (4.5 h) therapeutic window of exogenous tPA in ischemic stroke. Based on these results, we hypothesize that inhibiting MMPs and/or supplementing BM components may be beneficial in ischemic stroke. In agreement with this hypothesis, many broad-spectrum MMP inhibitors, including minocycline, doxycycline, GM6001 and BB-94, displayed protective effects in ischemic stroke,^178–181 although one study showed that intravenous injection of minocycline was safe but not effective.¹⁸² SB-3CT, an MMP-2/9 specific inhibitor, restored laminin degradation, reduced infarct volume, and improved neurological function in a mouse model of ischemic stroke.^183,184 In addition, many studies showed that MMP inhibitor-tPA combined therapies significantly reduced hemorrhagic complications of tPA.^{178,185–189} We are currently investigating the therapeutic effects of BM components in ischemic stroke.

Collagen IV changes in ischemic stroke

Unlike in hemorrhagic stroke, controversial results exist on how collagen IV level changes in ischemic stroke. Most studies support that collagen IV is reduced after ischemic stroke. For instance, reduced collagen IV levels were found in rats with thromboembolic¹⁹⁰ or suture^132,191 model of MCAO. In addition, substantial loss of collagen IV was also detected in non-human primate baboons (Papio anubis/cynocephalus) after ischemia-reperfusion injury.^172,192 Furthermore, an association between ischemic stroke and Col4a1 mutations was found in humans,^150,193,194 suggesting that collagen IV may be involved in the pathogenesis of ischemic stroke. In contrast to these results, one study found increased collagen IV expression in the spinal cord 24 h after ischemia–reperfusion injury.¹⁹⁵ In addition, it was also reported that MCAO alone without systemic inflammation failed to affect collagen IV level in the brain.¹⁹⁶ This discrepancy may be due to different organs examined (brain vs. spinal cord). Whether ischemic stroke affects collagen IV level in an organ-specific manner needs further investigation.

Laminin changes in ischemic stroke

Like collagen IV, laminin changes after ischemic stroke have been controversial. On one hand, there is evidence demonstrating that laminin is reduced after ischemic stroke. It has been shown that ischemic stroke increases the activity of MMP-9, which degrades laminin in mouse brain.¹⁸⁴ In addition, laminin expression is substantially decreased in Mongolian gerbils (Meriones unguiculatus) up to 72 h of reperfusion after ischemia.¹⁹⁷ Similarly, ischemia-reperfusion injury induces a gradual and continuous reduction of both laminin expression and laminin-positive vessel number in baboons.^172,192 Furthermore, diminished laminin level is also found in patients with ischemic stroke.¹⁹⁸ Interestingly, loss of laminin correlates well with the increase/activation of various proteases,^172,192,197 again suggesting that proteolytic degradation is responsible for the loss of laminin in ischemic stroke.

On the other hand, there is also evidence showing that laminin expression is unaffected or even enhanced after ischemic stroke. For example, laminin level was found unchanged in the brain after MCAO without systemic inflammation.¹⁹⁶ Laminin was also reported to be up-regulated in the ischemic core within 24 h after injury.^199,200 Additionally, astrocytes have been shown to express high levels of laminin two to three days after ischemia, which forms a barrier and separates the ischemic regions from healthy tissue.^199,200 Furthermore, it has been demonstrated that ischemia induces a transient up-regulation of laminin in the brain in a COX-2 dependent manner.²⁰¹

These paradoxical results may be explained by different animal models used and time points examined. In addition, distinct fixation methods may also contribute to this discrepancy. It has been shown that heavy formaldehyde fixation masks laminin antigen in the BM, while mild-moderate formaldehyde fixation reveals it.²⁰² Furthermore, it is worth mentioning that most of the above-mentioned studies used a pan-laminin antibody to examine laminin expression. It remains unclear whether different laminin isoforms have distinct susceptibility to ischemia and how these laminin isoforms change after ischemia. Future research should address these important questions.

Nidogen changes in ischemic stroke

Like in hemorrhagic stroke, nidogen changes in ischemic stroke are largely unknown. One in vitro study showed that oxidative stress, one pathological alteration found in ischemic stroke, enhanced nidogen expression in human BMECs,²⁰³ suggesting that nidogen may be up-regulated after ischemic stroke. Whether ischemic stroke increases nidogen expression in vivo and how nidogen affects the pathogenesis of ischemic stroke need further investigation.

HSPG changes in ischemic stroke

There is evidence showing that ischemic stroke decreases HSPG2 levels. One study reported a 43–63% reduction of HSPG2 within a few hours after ischemic injury in baboons,¹⁷² suggesting that HSPG2 is one of the most sensitive ECM proteins to proteolysis in ischemic brain.¹⁷² Unlike other ECM proteins, which get degraded, HSPG2 is cleaved into small fragments after stroke. For instance, high levels of HSPG2 domain V (endorepellin)^204,205 and its C-terminal fragment²⁰⁶ are detected in rodents in multiple ischemic stroke models. Consist with these reports, a similar result was found in humans with ischemic stroke.²⁰⁷ Further studies demonstrate that these HSPG2 fragments are bioactive and exert a beneficial role in ischemic stroke. It has been reported that these HSPG2 fragments are able to diminish ischemic volume, reduce neuronal death, modulate astrogliosis, enhance angiogenesis, and improve motor function.^204,206,208

Future directions

Due to its intrinsic complexity and technical difficulties in its research, the BM has been understudied. With advances in biochemistry and genetics, many valuable research tools (e.g. transgenic mouse lines) have been generated and substantial progress has been made in this field. Many important questions, however, remain to be answered. These questions include: when and where is each BM component expressed? What is the relative contribution of these BM components from each cell type? Is there functional compensation among different isoforms of ECM proteins? How do distinct laminin isoforms change after stroke? How do nidogen and HSPG2 levels change in hemorrhagic and ischemic stroke? How does each BM component affect the pathogenesis of hemorrhagic and ischemic stroke? Answers to these questions rely on the generation of cell-specific conditional knockouts, compound mutants (e.g. double knockouts), and/or inducible knockouts. Future studies should focus on generating these mutants and answering the above-mentioned questions.

Footnotes

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was partially supported by AHA Scientist Development Grant (16SDG29320001).

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

Hallmann

Zhang

Di Russo

, et al. The regulation of immune cell trafficking by the extracellular matrix. Curr Opin Cell Biol 2015; 36: 54–61.

Kalluri

. Basement membranes: structure, assembly and role in tumour angiogenesis. Nature Rev Cancer 2003; 3: 422–433.

Paulsson

. Basement membrane proteins: structure, assembly, and cellular interactions. Crit Rev Biochem Mol Biol 1992; 27: 93–127.

Yurchenco

. Basement membranes: cell scaffoldings and signaling platforms. Cold Spring Harbor Perspect Biol 2011; 3: pii: a004911.

Martin

Timpl

. Laminin and other basement membrane components. Annu Rev Cell Biol 1987; 3: 57–85.

Vracko

. Significance of basal lamina for regeneration of injured lung. Virchows Arch A Pathol Pathol Anat 1972; 355: 264–274.

Vracko

Benditt

. Basal lamina: the scaffold for orderly cell replacement. Observations on regeneration of injured skeletal muscle fibers and capillaries. J Cell Biol 1972; 55: 406–419.

Vracko

Benditt

. Capillary basal lamina thickening. Its relationship to endothelial cell death and replacement. J Cell Biol 1970; 47: 281–285.

Vracko

. Basal lamina scaffold-anatomy and significance for maintenance of orderly tissue structure. Am J Pathol 1974; 77: 314–346.

10.

Vracko

Strandness

Jr . Basal lamina of abdominal skeletal muscle capillaries in diabetics and nondiabetics. Circulation 1967; 35: 690–700.

11.

Ruben

Yurchenco

. High resolution platinum-carbon replication of freeze-dried basement membrane. Microscopy Res Tech 1994; 28: 13–28.

12.

Yurchenco

Amenta

Patton

. Basement membrane assembly, stability and activities observed through a developmental lens. Matrix Biol 2004; 22: 521–538.

13.

Sorokin

. The impact of the extracellular matrix on inflammation. Nat Rev Immunol 2010; 10: 712–723.

14.

Yurchenco

Schittny

. Molecular architecture of basement membranes. FASEB J 1990; 4: 1577–1590.

15.

Schittny

Yurchenco

. Basement membranes: molecular organization and function in development and disease. Curr Opin Cell Biol 1989; 1: 983–988.

16.

Erickson

Couchman

. Still more complexity in mammalian basement membranes. J Histochem Cytochem 2000; 48: 1291–1306.

17.

Myers

Dion

Abraham

, et al. Type XV collagen exhibits a widespread distribution in human tissues but a distinct localization in basement membrane zones. Cell Tissue Res 1996; 286: 493–505.

18.

Myers

Bageris

, et al. Biochemical and immunohistochemical characterization of human type XIX defines a novel class of basement membrane zone collagens. Am J Pathol 1997; 151: 1729–1740.

19.

Saarela

Rehn

Oikarinen

, et al. The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. Am J Pathol 1998; 153: 611–626.

20.

Tomono

Naito

Ando

, et al. Epitope-defined monoclonal antibodies against multiplexin collagens demonstrate that type XV and XVIII collagens are expressed in specialized basement membranes. Cell Struct Funct 2002; 27: 9–20.

21.

Sixt

Engelhardt

Pausch

, et al. Endothelial cell laminin isoforms, laminins 8 and 10, play decisive roles in T cell recruitment across the blood-brain barrier in experimental autoimmune encephalomyelitis. J Cell Biol 2001; 153: 933–946.

22.

Hallmann

Horn

Selg

, et al. Expression and function of laminins in the embryonic and mature vasculature. Physiol Rev 2005; 85: 979–1000.

23.

Owens

Bechmann

Engelhardt

. Perivascular spaces and the two steps to neuroinflammation. J Neuropathol Exp Neurol 2008; 67: 1113–1121.

24.

van Horssen

Vos

, et al. Basement membrane proteins in multiple sclerosis-associated inflammatory cuffs: potential role in influx and transport of leukocytes. J Neuropathol Exp Neurol 2005; 64: 722–729.

25.

Hudson

Reeders

Tryggvason

. Type IV collagen: structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. J Biol Chem 1993; 268: 26033–26036.

26.

Kalluri

. Discovery of type IV collagen non-collagenous domains as novel integrin ligands and endogenous inhibitors of angiogenesis. Cold Spring Harb Symp Quant Biol 2002; 67: 255–266.

27.

Filie

Burbelo

Kozak

. Genetic mapping of the alpha 1 and alpha 2 (IV) collagen genes to mouse chromosome 8. Mamm Genome 1995; 6: 487.

28.

Sugimoto

Oohashi

Ninomiya

. The genes COL4A5 and COL4A6, coding for basement membrane collagen chains alpha 5(IV) and alpha 6(IV), are located head-to-head in close proximity on human chromosome Xq22 and COL4A6 is transcribed from two alternative promoters. Proc Natl Acad Sci U S A 1994; 91: 11679–11683.

29.

Soininen

Huotari

Hostikka

, et al. The structural genes for alpha 1 and alpha 2 chains of human type IV collagen are divergently encoded on opposite DNA strands and have an overlapping promoter region. J Biol Chem 1988; 263: 17217–17220.

30.

Momota

Sugimoto

Oohashi

, et al. Two genes, COL4A3 and COL4A4 coding for the human alpha3(IV) and alpha4(IV) collagen chains are arranged head-to-head on chromosome 2q36. FEBS Lett 1998; 424: 11–16.

31.

Khoshnoodi

Pedchenko

Hudson

. Mammalian collagen IV. Microscopy Res Tech 2008; 71: 357–370.

32.

Vanacore

Shanmugasundararaj

Friedman

, et al. The alpha1.alpha2 network of collagen IV. Reinforced stabilization of the noncollagenous domain-1 by noncovalent forces and the absence of Met-Lys cross-links. J Biol Chem 2004; 279: 44723–44730.

33.

Webersinke

Bauer

Amberger

, et al. Comparison of gene expression of extracellular matrix molecules in brain microvascular endothelial cells and astrocytes. Biochem Biophys Res Commun 1992; 189: 877–884.

34.

Tilling

Engelbertz

Decker

, et al. Expression and adhesive properties of basement membrane proteins in cerebral capillary endothelial cell cultures. Cell Tissue Res 2002; 310: 19–29.

35.

Stratman

Malotte

Mahan

, et al. Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation. Blood 2009; 114: 5091–5101.

36.

Kose

Asashima

Muta

, et al. Altered expression of basement membrane-related molecules in rat brain pericyte, endothelial, and astrocyte cell lines after transforming growth factor-beta1 treatment. Drug Metab Pharmacokinet 2007; 22: 255–266.

37.

Allt

Lawrenson

. Pericytes: cell biology and pathology. Cells Tissues Organs 2001; 169: 1–11.

38.

Miner

Yurchenco

. Laminin functions in tissue morphogenesis. Annu Rev Cell Dev Biol 2004; 20: 255–284.

39.

Domogatskaya

Rodin

Tryggvason

. Functional diversity of laminins. Annu Rev Cell Dev Biol 2012; 28: 523–553.

40.

Colognato

Yurchenco

. Form and function: the laminin family of heterotrimers. Develop Dyn 2000; 218: 213–234.

41.

Yao

. Laminin: loss-of-function studies. Cell Mol Life Sci 2017; 74: 1095–1115.

42.

Aumailley

. The laminin family. Cell Adhes Migrat 2013; 7: 48–55.

43.

Aumailley

Bruckner-Tuderman

Carter

, et al. A simplified laminin nomenclature. Matrix Biol 2005; 24: 326–332.

44.

Durbeej

. Laminins. Cell Tissue Res 2010; 339: 259–268.

45.

McKee

Harrison

Capizzi

, et al. Role of laminin terminal globular domains in basement membrane assembly. J Biol Chem 2007; 282: 21437–21447.

46.

Burgeson

Chiquet

Deutzmann

, et al. A new nomenclature for the laminins. Matrix Biol 1994; 14: 209–211.

47.

Baeten

Akassoglou

. Extracellular matrix and matrix receptors in blood-brain barrier formation and stroke. Develop Neurobiol 2011; 71: 1018–1039.

48.

Nirwane

Yao

. Laminins and their receptors in the CNS. Biol Rev Cambridge Philos Soc 2018. In print.

49.

Sorokin

Pausch

Frieser

, et al. Developmental regulation of the laminin alpha5 chain suggests a role in epithelial and endothelial cell maturation. Develop Biol 1997; 189: 285–300.

50.

Hannocks

Pizzo

Huppert

, et al. Molecular characterization of perivascular drainage pathways in the murine brain. J Cereb Blood Flow Metab 2018; 38: 669–686.

51.

Jucker

Tian

Norton

, et al. Laminin alpha 2 is a component of brain capillary basement membrane: reduced expression in dystrophic dy mice. Neuroscience 1996; 71: 1153–1161.

52.

Grimpe

Probst

Hager

. Suppression of nidogen-1 translation by antisense targeting affects the adhesive properties of cultured astrocytes. Glia 1999; 28: 138–149.

53.

Brachvogel

Pausch

Farlie

, et al. Isolated Anxa5+/Sca-1+ perivascular cells from mouse meningeal vasculature retain their perivascular phenotype in vitro and in vivo. Exp Cell Res 2007; 313: 2730–2743.

54.

Farach-Carson

Carson

. Perlecan – a multifunctional extracellular proteoglycan scaffold. Glycobiology 2007; 17: 897–905.

55.

Whitelock

Melrose

Iozzo

. Diverse cell signaling events modulated by perlecan. Biochemistry 2008; 47: 11174–11183.

56.

Roberts

Kahle

Bix

. Perlecan and the blood-brain barrier: beneficial proteolysis? Front Pharmacol 2012; 3: 155.

57.

Gubbiotti

Neill

Iozzo

. A current view of perlecan in physiology and pathology: a mosaic of functions. Matrix Biol 2017; 57–58: 285–298.

58.

Costell

Sasaki

Mann

, et al. Structural characterization of recombinant domain II of the basement membrane proteoglycan perlecan. FEBS Lett 1996; 396: 127–131.

59.

Crossin

Krushel

. Cellular signaling by neural cell adhesion molecules of the immunoglobulin superfamily. Develop Dyn 2000; 218: 260–279.

60.

Dolan

Horchar

Rigatti

, et al. Identification of sites in domain I of perlecan that regulate heparan sulfate synthesis. J Biol Chem 1997; 272: 4316–4322.

61.

Fjeldstad

Kolset

. Decreasing the metastatic potential in cancers – targeting the heparan sulfate proteoglycans. Curr Drug Targets 2005; 6: 665–682.

62.

Hopf

Gohring

Mann

, et al. Mapping of binding sites for nidogens, fibulin-2, fibronectin and heparin to different IG modules of perlecan. J Mol Biol 2001; 311: 529–541.

63.

Jiang

Couchman

. Perlecan and tumor angiogenesis. J Histochem Cytochem 2003; 51: 1393–1410.

64.

Merz

Alves

Kawano

, et al. UNC-52/perlecan affects gonadal leader cell migrations in C. elegans hermaphrodites through alterations in growth factor signaling. Develop Biol 2003; 256: 173–186.

65.

Yang

. Wnts and wing: Wnt signaling in vertebrate limb development and musculoskeletal morphogenesis. Birth Defects Res C Embryo Today 2003; 69: 305–317.

66.

Zhang

Chuang

Swanson

, et al. Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood 2004; 103: 1185–1191.

67.

Kojima

Leone

Marchildon

, et al. Isolation and characterization of heparan sulfate proteoglycans produced by cloned rat microvascular endothelial cells. J Biol Chem 1992; 267: 4859–4869.

68.

Forsten

Courant

Nugent

. Endothelial proteoglycans inhibit bFGF binding and mitogenesis. J Cell Physiol 1997; 172: 209–220.

69.

Garcia de Yebenes

Damani

, et al. Regulation of the heparan sulfate proteoglycan, perlecan, by injury and interleukin-1alpha. J Neurochem 1999; 73: 812–820.

70.

Santos-Silva

Fairless

Frame

, et al. FGF/heparin differentially regulates Schwann cell and olfactory ensheathing cell interactions with astrocytes: a role in astrocytosis. J Neurosci Neuroscience 2007; 27: 7154–7167.

71.

Di Russo

Hannocks

Luik

, et al. Vascular laminins in physiology and pathology. Matrix Biol 2017; 57–58: 140–148.

72.

Furie

Naprstek

Silverstein

. Migration of neutrophils across monolayers of cultured microvascular endothelial cells. An in vitro model of leucocyte extravasation. J Cell Sci 1987; 88(Pt 2): 161–175.

73.

Hurley

. An electron microscopic study of leucocytic emigration and vascular permeability in rat skin. Aust J Exp Biol Med Sci 1963; 41: 171–186.

74.

Marchesi

Florey

. Electron micrographic observations on the emigration of leucocytes. Q J Exp Physiol Cogn Med Sci 1960; 45: 343–348.

75.

Ohashi

Tung

Wilson

, et al. Transvascular and interstitial migration of neutrophils in rat mesentery. Microcirculation 1996; 3: 199–210.

76.

Hoshi

Ushiki

. Neutrophil extravasation in rat mesenteric venules induced by the chemotactic peptide N-formyl-methionyl-luecylphenylalanine (fMLP), with special attention to a barrier function of the vascular basal lamina for neutrophil migration. Arch Histol Cytol 2004; 67: 107–114.

77.

Yadav

Larbi

Young

, et al. Migration of leukocytes through the vessel wall and beyond. Thromb Haemos 2003; 90: 598–606.

78.

Bixel

Petri

Khandoga

, et al. A CD99-related antigen on endothelial cells mediates neutrophil but not lymphocyte extravasation in vivo. Blood 2007; 109: 5327–5336.

79.

Bartholomaus

Kawakami

Odoardi

, et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009; 462: 94–98.

80.

Engelhardt

Ransohoff

. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol 2012; 33: 579–589.

81.

Zlokovic

. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178–201.

82.

Poschl

Schlotzer-Schrehardt

Brachvogel

, et al. Collagen IV is essential for basement membrane stability but dispensable for initiation of its assembly during early development. Development 2004; 131: 1619–1628.

83.

Kuo

Labelle-Dumais

Mao

, et al. Allelic heterogeneity contributes to variability in ocular dysgenesis, myopathy and brain malformations caused by Col4a1 and Col4a2 mutations. Hum Mol Genet 2014; 23: 1709–1722.

84.

Favor

Gloeckner

Janik

, et al. Type IV procollagen missense mutations associated with defects of the eye, vascular stability, the brain, kidney function and embryonic or postnatal viability in the mouse, Mus musculus: an extension of the Col4a1 allelic series and the identification of the first two Col4a2 mutant alleles. Genetics 2007; 175: 725–736.

85.

Jeanne

Jorgensen

Gould

. Molecular and genetic analyses of collagen type IV mutant mouse models of spontaneous intracerebral hemorrhage identify mechanisms for stroke prevention. Circulation 2015; 131: 1555–1565.

86.

Thyboll

Kortesmaa

Cao

, et al. Deletion of the laminin alpha4 chain leads to impaired microvessel maturation. Mol Cell Biol 2002; 22: 1194–1202.

87.

Ivars

Anderson

, et al. Endothelial basement membrane laminin α5 selectively inhibits T lymphocyte extravasation into the brain. Nat Med 2009; 15: 519–527.

88.

Miner

Cunningham

Sanes

. Roles for laminin in embryogenesis: exencephaly, syndactyly, and placentopathy in mice lacking the laminin alpha5 chain. J Cell Biol 1998; 143: 1713–1723.

89.

Miner

Mudd

, et al. Compositional and structural requirements for laminin and basement membranes during mouse embryo implantation and gastrulation. Development 2004; 131: 2247–2256.

90.

Yin

Kikkawa

Mudd

, et al. Expression of laminin chains by central neurons: analysis with gene and protein trapping techniques. Genesis 2003; 36: 114–127.

91.

Smyth

Vatansever

Meyer

, et al. The targeted deletion of the LAMC1 gene. Ann N Y Acad Sci 1998; 857: 283–286.

92.

Smyth

Vatansever

Murray

, et al. Absence of basement membranes after targeting the LAMC1 gene results in embryonic lethality due to failure of endoderm differentiation. J Cell Biol 1999; 144: 151–160.

93.

Song

Lokmic

Lämmermann

, et al. Extracellular matrix of secondary lymphoid organs impacts on B-cell fate and survival. Proc Natl Acad Sci U S A 2013; 110: E2915–E2924.

94.

Song

Zhang

Buscher

, et al. Endothelial basement membrane laminin 511 contributes to endothelial junctional tightness and thereby inhibits leukocyte transmigration. Cell Rep 2017; 18: 1256–1269.

95.

Chen

Z-L

Strickland

. Laminin γ1 is critical for Schwann cell differentiation, axon myelination, and regeneration in the peripheral nerve. J Cell Biol 2003; 163: 889–899.

96.

Yao

Chen

Norris

, et al. Astrocytic laminin regulates pericyte differentiation and maintains blood brain barrier integrity. Nat Commun 2014; 5: 3413.

97.

Chen

Yao

Norris

, et al. Ablation of astrocytic laminin impairs vascular smooth muscle cell function and leads to hemorrhagic stroke. J Cell Biol 2013; 202: 381–395.

98.

Menezes

McClenahan

Leiton

, et al. The extracellular matrix protein laminin alpha2 regulates the maturation and function of the blood-brain barrier. J Neurosci 2014; 34: 15260–15280.

99.

Vanlandewijck

Mae

, et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature 2018; 554: 475–480.

100.

Armulik

Genove

Betsholtz

. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Develop Cell 2011; 21: 193–215.

101.

Gautam

Zhang

Yao

. The role of pericytic laminin in blood brain barrier integrity maintenance. Sci Rep 2016; 6: 36450.

102.

Yao

Norris

Strickland

. The cellular origin of laminin determines its role in blood pressure regulation. Cell Mol Life Sci 2015; 72: 999–1008.

103.

Threadgill

Dlugosz

Hansen

, et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995; 269: 230–234.

104.

Bonyadi

Rusholme

Cousins

, et al. Mapping of a major genetic modifier of embryonic lethality in TGF beta 1 knockout mice. Nat Genet 1997; 15: 207–211.

105.

Heiman-Patterson

Sher

Blankenhorn

, et al. Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: a window of opportunity in the search for genetic modifiers. Amyotroph Lateral Scler 2011; 12: 79–86.

106.

George

Georges-Labouesse

Patel-King

, et al. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 1993; 119: 1079–1091.

107.

Kang

Kramer

. Nidogen is nonessential and not required for normal type IV collagen localization in Caenorhabditis elegans. Mol Biol Cell 2000; 11: 3911–3923.

108.

Murshed

Smyth

Miosge

, et al. The absence of nidogen 1 does not affect murine basement membrane formation. Mol Cell Biol 2000; 20: 7007–7012.

109.

Dong

Chen

Lewis

, et al. Neurologic defects and selective disruption of basement membranes in mice lacking entactin-1/nidogen-1. Labor Invest 2002; 82: 1617–1630.

110.

May

. Distribution of nidogen in the murine eye and ocular phenotype of the nidogen-1 knockout mouse. ISRN Ophthalmol 2012; 2012: 378641.

111.

Schymeinsky

Nedbal

Miosge

, et al. Gene structure and functional analysis of the mouse nidogen-2 gene: nidogen-2 is not essential for basement membrane formation in mice. Mol Cell Biol 2002; 22: 6820–6830.

112.

Bader

Smyth

Nedbal

, et al. Compound genetic ablation of nidogen 1 and 2 causes basement membrane defects and perinatal lethality in mice. Mol Cell Biol 2005; 25: 6846–6856.

113.

Bose

Nischt

Page

, et al. Loss of nidogen-1 and -2 results in syndactyly and changes in limb development. J Biol Chem 2006; 281: 39620–39629.

114.

Costell

Gustafsson

Aszodi

, et al. Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol 1999; 147: 1109–1122.

115.

Arikawa-Hirasawa

Watanabe

Takami

, et al. Perlecan is essential for cartilage and cephalic development. Nat Genet 1999; 23: 354–358.

116.

Writing Group

Mozaffarian

Benjamin

, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 2016; 133: e38–60.

117.

Voisin

Woodfin

Nourshargh

. Monocytes and neutrophils exhibit both distinct and common mechanisms in penetrating the vascular basement membrane in vivo. Arterioscler Thromb Vasc Biol 2009; 29: 1193–1199.

118.

Wang

Voisin

Larbi

, et al. Venular basement membranes contain specific matrix protein low expression regions that act as exit points for emigrating neutrophils. J Exp Med 2006; 203: 1519–1532.

119.

Wang

Cao

Chen

, et al. Pericytes regulate vascular basement membrane remodeling and govern neutrophil extravasation during inflammation. PLoS One 2012; 7: e45499.

120.

Voisin

Probstl

Nourshargh

. Venular basement membranes ubiquitously express matrix protein low. Am J Pathol 2010; 176: 482–495.

121.

Warren

Iwami

Harris

, et al. Laminins affect T cell trafficking and allograft fate. J Clin Invest 2014; 124: 2204–2218.

122.

Scholler

Trinkl

Klopotowski

, et al. Characterization of microvascular basal lamina damage and blood-brain barrier dysfunction following subarachnoid hemorrhage in rats. Brain Res 2007; 1142: 237–246.

123.

Hynes

. Stretching the boundaries of extracellular matrix research. Nat Rev Mol Cell Biol 2014; 15: 761–763.

124.

Power

Henry

Del Bigio

, et al. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol 2003; 53: 731–742.

125.

Tejima

Zhao

Tsuji

, et al. Astrocytic induction of matrix metalloproteinase-9 and edema in brain hemorrhage. J Cereb Blood Flow Metab 2007; 27: 460–468.

126.

Rosell

Ortega-Aznar

Alvarez-Sabin

, et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 2006; 37: 1399–1406.

127.

Alvarez-Sabin

Delgado

Abilleira

, et al. Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke 2004; 35: 1316–1322.

128.

Xue

Fan

Liu

, et al. Contributions of multiple proteases to neurotoxicity in a mouse model of intracerebral haemorrhage. Brain 2009; 132: 26–36.

129.

Xue

Del Bigio

. Acute tissue damage after injections of thrombin and plasmin into rat striatum. Stroke 2001; 32: 2164–2169.

130.

Hua

Keep

, et al. Thrombin and brain recovery after intracerebral hemorrhage. Stroke 2009; 40: S88–S89.

131.

Cunningham

Wetzel

Rosenberg

. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005; 50: 329–339.

132.

Hamann

Liebetrau

Martens

, et al. Microvascular basal lamina injury after experimental focal cerebral ischemia and reperfusion in the rat. J Cereb Blood Flow Metab 2002; 22: 526–533.

133.

Rosenberg

Estrada

Mobashery

. Effect of synthetic matrix metalloproteinase inhibitors on lipopolysaccharide-induced blood-brain barrier opening in rodents: differences in response based on strains and solvents. Brain Res 2007; 1133: 186–192.

134.

Wang

Tsirka

. Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain 2005; 128: 1622–1633.

135.

Grossetete

Rosenberg

. Matrix metalloproteinase inhibition facilitates cell death in intracerebral hemorrhage in mouse. J Cereb Blood Flow Metab 2008; 28: 752–763.

136.

Chang

Kim-Tenser

Emanuel

, et al. Minocycline and matrix metalloproteinase inhibition in acute intracerebral hemorrhage: a pilot study. Eur J Neurol 2017; 24: 1384–1391.

137.

Weinl

Castaneda Vega

Riehle

, et al. Endothelial depletion of murine SRF/MRTF provokes intracerebral hemorrhagic stroke. Proc Natl Acad Sci U S A 2015; 112: 9914–9919.

138.

Rosell

Cuadrado

Ortega-Aznar

, et al. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008; 39: 1121–1126.

139.

Wang

Tsirka

. Tuftsin fragment 1-3 is beneficial when delivered after the induction of intracerebral hemorrhage. Stroke 2005; 36: 613–618.

140.

Wang

Rogove

Tsirka

, et al. Protective role of tuftsin fragment 1-3 in an animal model of intracerebral hemorrhage. Ann Neurol 2003; 54: 655–664.

141.

Wang

Tsirka

. Contribution of extracellular proteolysis and microglia to intracerebral hemorrhage. Neurocrit Care 2005; 3: 77–85.

142.

Gould

Phalan

Breedveld

, et al. Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly. Science 2005; 308: 1167–1171.

143.

Gould

Phalan

van Mil

, et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med 2006; 354: 1489–1496.

144.

Jeanne

Labelle-Dumais

Jorgensen

, et al. COL4A2 mutations impair COL4A1 and COL4A2 secretion and cause hemorrhagic stroke. Am J Hum Genet 2012; 90: 91–101.

145.

de Vries

Mancini

. Intracerebral hemorrhage and COL4A1 and COL4A2 mutations, from fetal life into adulthood. Ann Neurol 2012; 71: 439–441.

146.

Gunda

Mine

Kovacs

, et al. COL4A2 mutation causing adult onset recurrent intracerebral hemorrhage and leukoencephalopathy. J Neurol 2014; 261: 500–503.

147.

Corlobe

Tournier-Lasserve

Mine

, et al. COL4A1 mutation revealed by an isolated brain hemorrhage. Cerebrovas Dis 2013; 35: 593–594.

148.

de Vries

Koopman

Groenendaal

, et al. COL4A1 mutation in two preterm siblings with antenatal onset of parenchymal hemorrhage. Ann Neurol 2009; 65: 12–18.

149.

Shah

Kumar

McLean

, et al. A dominantly inherited mutation in collagen IV A1 (COL4A1) causing childhood onset stroke without porencephaly. Eur J Paediat Neurol 2010; 14: 182–187.

150.

Breedveld

de Coo

Lequin

, et al. Novel mutations in three families confirm a major role of COL4A1 in hereditary porencephaly. J Med Genet 2006; 43: 490–495.

151.

Lichtenbelt

Pistorius

De Tollenaer

, et al. Prenatal genetic confirmation of a COL4A1 mutation presenting with sonographic fetal intracranial hemorrhage. Ultrasound Obstet Gynecol 2012; 39: 726–727.

152.

Garel

Rosenblatt

Moutard

, et al. Fetal intracerebral hemorrhage and COL4A1 mutation: promise and uncertainty. Ultrasound Obstet Gynecol 2013; 41: 228–230.

153.

Colin

Sentilhes

Sarfati

, et al. Fetal intracerebral hemorrhage and cataract: think COL4A1. J Perinatology 2014; 34: 75–77.

154.

Weng

Sonni

Labelle-Dumais

, et al. COL4A1 mutations in patients with sporadic late-onset intracerebral hemorrhage. Ann Neurol 2012; 71: 470–477.

155.

van der Knaap

Smit

Barkhof

, et al. Neonatal porencephaly and adult stroke related to mutations in collagen IV A1. Ann Neurol 2006; 59: 504–511.

156.

Vahedi

Massin

Guichard

, et al. Hereditary infantile hemiparesis, retinal arteriolar tortuosity, and leukoencephalopathy. Neurology 2003; 60: 57–63.

157.

Bilguvar

DiLuna

Bizzarro

, et al. COL4A1 mutation in preterm intraventricular hemorrhage. J Pediat 2009; 155: 743–745.

158.

Lanfranconi

Markus

. COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review. Stroke 2010; 41: e513–e518.

159.

Hamann

Okada

del Zoppo

. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab 1996; 16: 1373–1378.

160.

Liu

Gao

Feener

. Proteomic identification of novel plasma kallikrein substrates in the astrocyte secretome. Transl Stroke Res 2010; 1: 276–286.

161.

Hamann

Burggraf

Martens

, et al. Mild to moderate hypothermia prevents microvascular basal lamina antigen loss in experimental focal cerebral ischemia. Stroke 2004; 35: 764–769.

162.

Yepes

Sandkvist

Wong

, et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000; 96: 569–576.

163.

Nahirney

Reeson

Brown

. Ultrastructural analysis of blood-brain barrier breakdown in the peri-infarct zone in young adult and aged mice. J Cereb Blood Flow Metab 2016; 36: 413–425.

164.

Kwon

Kim

del Zoppo

, et al. Ultrastructural and temporal changes of the microvascular basement membrane and astrocyte interface following focal cerebral ischemia. J Neurosci Res 2009; 87: 668–676.

165.

Wang

Shuaib

. Critical role of microvasculature basal lamina in ischemic brain injury. Prog Neurobiol 2007; 83: 140–148.

166.

Fujimura

Gasche

Morita-Fujimura

, et al. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 1999; 842: 92–100.

167.

Gasche

Fujimura

Morita-Fujimura

, et al. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 1999; 19: 1020–1028.

168.

Heo

Lucero

Abumiya

, et al. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999; 19: 624–633.

169.

Romanic

White

Arleth

, et al. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998; 29: 1020–1030.

170.

Rosenberg

. Matrix metalloproteinases in neuroinflammation. Glia 2002; 39: 279–291.

171.

Rosenberg

Navratil

Barone

, et al. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 1996; 16: 360–366.

172.

Fukuda

Fini

Mabuchi

, et al. Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke 2004; 35: 998–1004.

173.

Seyfried

Han

Zheng

, et al. Cathepsin B and middle cerebral artery occlusion in the rat. J Neurosurg 1997; 87: 716–723.

174.

Niego

Medcalf

. Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis? J Cereb Blood Flow Metab 2014; 34: 1283–1296.

175.

Aoki

Sumii

Mori

, et al. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 2002; 33: 2711–2717.

176.

Tsuji

Aoki

Tejima

, et al. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 2005; 36: 1954–1959.

177.

Wang

Lee

Arai

, et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003; 9: 1313–1317.

178.

Asahi

Jung

, et al. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000; 20: 1681–1689.

179.

Pires

Rogers

McClain

, et al. Doxycycline, a matrix metalloprotease inhibitor, reduces vascular remodeling and damage after cerebral ischemia in stroke-prone spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2011; 301: H87–H97.

180.

Chen

Hartman

Ayer

, et al. Matrix metalloproteinases inhibition provides neuroprotection against hypoxia-ischemia in the developing brain. J Neurochem 2009; 111: 726–736.

181.

Fagan

Cronic

Hess

. Minocycline development for acute ischemic stroke. Transl Stroke Res 2011; 2: 202–208.

182.

Kohler

Prentice

Bates

, et al. Intravenous minocycline in acute stroke: a randomized, controlled pilot study and meta-analysis. Stroke 2013; 44: 2493–2499.

183.

Cui

Chen

Zhang

, et al. Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. Mol Neurodegenerat 2012; 7: 21.

184.

Cui

Brown

, et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 2005; 25: 6401–6408.

185.

Lapchak

Chapman

Zivin

. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000; 31: 3034–3040.

186.

Mishiro

Ishiguro

Suzuki

, et al. A broad-spectrum matrix metalloproteinase inhibitor prevents hemorrhagic complications induced by tissue plasminogen activator in mice. Neuroscience 2012; 205: 39–48.

187.

Murata

Rosell

Scannevin

, et al. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke 2008; 39: 3372–3377.

188.

Lampl

Boaz

Gilad

, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007; 69: 1404–1410.

189.

Switzer

Hess

Ergul

, et al. Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke 2011; 42: 2633–2635.

190.

Vosko

Busch

Burggraf

, et al. Microvascular basal lamina damage in thromboembolic stroke in a rat model. Neurosci Lett 2003; 353: 217–220.

191.

Trinkl

Vosko

Wunderlich

, et al. Pravastatin reduces microvascular basal lamina damage following focal cerebral ischemia and reperfusion. Eur J Neurosci 2006; 24: 520–526.

192.

Hamann

Okada

Fitridge

, et al. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 1995; 26: 2120–2126.

193.

Sibon

Coupry

Menegon

, et al. COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy and stroke. Ann Neurol 2007; 62: 177–184.

194.

Plaisier

Gribouval

Alamowitch

, et al. COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. N Engl J Med 2007; 357: 2687–2695.

195.

Anik

Kokturk

Genc

, et al. Immunohistochemical analysis of TIMP-2 and collagen types I and IV in experimental spinal cord ischemia-reperfusion injury in rats. J Spinal Cord Med 2011; 34: 257–264.

196.

McColl

Rothwell

Allan

. Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice. J Neurosci 2008; 28: 9451–9462.

197.

Zalewska

Ziemka-Nalecz

Sarnowska

, et al. Transient forebrain ischemia modulates signal transduction from extracellular matrix in gerbil hippocampus. Brain Res 2003; 977: 62–69.

198.

Horstmann

Kalb

Koziol

, et al. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003; 34: 2165–2170.

199.

Liesi

Kaakkola

Dahl

, et al. Laminin is induced in astrocytes of adult brain by injury. EMBO J 1984; 3: 683–686.

200.

Jucker

Bialobok

Kleinman

, et al. Laminin-like and laminin-binding protein-like immunoreactive astrocytes in rat hippocampus after transient ischemia. Antibody to laminin-binding protein is a sensitive marker of neural injury and degeneration. Ann N Y Acad Sci 1993; 679: 245–252.

201.

Tsirka

. Inflammation modulates expression of laminin in the central nervous system following ischemic injury. J Neuroinflamm 2012; 9: 159.

202.

Jucker

Bialobok

Hagg

, et al. Laminin immunohistochemistry in brain is dependent on method of tissue fixation. Brain Res 1992; 586: 166–170.

203.

Ning

Sarracino

Kho

, et al. Proteomic temporal profile of human brain endothelium after oxidative stress. Stroke 2011; 42: 37–43.

204.

Lee

Clarke

Al Ahmad

, et al. Perlecan domain V is neuroprotective and proangiogenic following ischemic stroke in rodents. J Clin Invest 2011; 121: 3005–3023.

205.

Bix

Gowing

Clarkson

. Perlecan domain V is neuroprotective and affords functional improvement in a photothrombotic stroke model in young and aged mice. Transl Stroke Res 2013; 4: 515–523.

206.

Saini

Pinteaux

Lee

, et al. Oxygen-glucose deprivation and interleukin-1alpha trigger the release of perlecan LG3 by cells of neurovascular unit. J Neurochem 2011; 119: 760–771.

207.

Kahle

Lee

Pourmohamad

, et al. Perlecan domain V is upregulated in human brain arteriovenous malformation and could mediate the vascular endothelial growth factor effect in lesional tissue. Neuroreport 2012; 23: 627–630.

208.

Al-Ahmad

Lee

Saini

, et al. Perlecan domain V modulates astrogliosis in vitro and after focal cerebral ischemia through multiple receptors and increased nerve growth factor release. Glia 2011; 59: 1822–1840.

Basement membrane and stroke

Abstract

Keywords

Introduction

BM composition

Collagen IV

Laminin

Nidogen

HSPG

BM and BBB

Collagen IV

Laminin

Nidogen

HSPG

BM and stroke

BM and hemorrhagic stroke

Collagen IV changes in hemorrhagic stroke

Laminin changes in hemorrhagic stroke

Nidogen changes in hemorrhagic stroke

HSPG changes in hemorrhagic stroke

BM and ischemic stroke

Collagen IV changes in ischemic stroke

Laminin changes in ischemic stroke

Nidogen changes in ischemic stroke

HSPG changes in ischemic stroke

Future directions

Footnotes

Funding

Declaration of conflicting interests

References